2016-11-15T09:49:15-06:00 2015-12-31 BDO USA LLP 8401 GREENSBORO DRIVE SUITE 800 MCLEAN VA 22102 990 2015-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC % LINDA JENSEN CFO AMER 5714831300 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 LINDA JENSEN CFO 5714831300 2016-11-09 true Marc Berger P01871563 7038930600 2015 2017-02-10 21:41:12Z CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 188136952 false X WWW.ASCO.ORG X 1964 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY PATIENT CARE. 18 18 479 1200 17203768 4775701 9852055 13960857 83008682 88958786 7150343 2187851 1917561 2266867 101928641 107374361 1900652 4171146 0 0 34296368 40035505 0 0 3855893 51865291 62544536 88062311 106751187 13866330 623174 217539280 209312844 112809634 110197622 104729646 99115222 X ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY CARE. ASCO VISION STATEMENTS: -- ALL CANCER PATIENTS WILL HAVE LIFELONG ACCESS TO HIGH QUALITY, EFFECTIVE, AFFORDABLE AND COMPASSIONATE CARE. -- THE MOST ACCURATE CANCER INFORMATION WILL BE AVAILABLE SO THAT PATIENTS AND PHYSICIANS CAN MAKE INFORMED DECISIONS ABOUT CANCER PREVENTION AND TREATMENT. -- INFORMATION WE LEARN FROM EVERY PATIENT WILL BE USED TO ACCELERATE PROGRESS AGAINST CANCER. -- RESOURCES WILL EXIST TO ATTRACT THE BEST CLINICIANS AND INVESTIGATORS TO PROVIDE OPTIMAL PATIENT CARE AND TO CONDUCT TRANSFORMATIVE RESEARCH. --ASCO WILL BE RECOGNIZED AS THE MOST TRUSTED SOURCE OF CANCER INFORMATION WORLDWIDE. false false 39289644 3590038 57302540 EDUCATIONAL AND SCIENTIFIC MEETINGS AND PRODUCTS: ASCO PROVIDES EDUCATIONAL AND SCIENTIFIC PROGRAMS AND CONTENT ON A VARIETY OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON CUTTING EDGE RESEARCH AND SCIENCE IN THE FIELD OF CLINICAL ONCOLOGY. THE SCIENTIFIC RESEARCH AND EDUCATION PRESENTED AT THE MEETINGS ENHANCES KNOWLEDGE ABOUT CANCER, THUS ADVANCING HIGH-QUALITY CANCER CARE. THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER EDUCATIONAL AND SCIENTIFIC MEETING IN THE ONCOLOGY COMMUNITY AND THE THEMATIC MEETINGS PRESENTED OR CO-SPONSORED BY ASCO PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC PROGRAMMING ON SPECIFIC TYPES OF CANCERS. ASCO'S EDUCATIONAL AND SCIENTIFIC PROGRAMS SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE AND ASSIST THEM IN PROVIDING WORLD CLASS CANCER CARE AND IN CONDUCTING CUTTING EDGE RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. APPROPRIATE PROGRAMS ARE PROVIDED FOR ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, AND OTHERS TO MEET THE CHANGING NEEDS OF PEOPLE LIVING WITH CANCER AND ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS SO THAT THEY ARE BETTER PREPARED TO MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY,ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM. ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT AVAILABLE TO THE GENERAL PUBLIC THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES EDUCATIONAL AND SCIENTIFIC MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2015 ACTIVITIES INCLUDE: OVER 38,000 PEOPLE ATTENDED THE 2015 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES,CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. MORE THAN HALF OF ATTENDEES AT THE 2015 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2015 ANNUAL MEETING FEATURED OVER 220 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 4,500 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 3,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY. IN ADDITION TO THE ASCO ANNUAL MEETING, ASCO SPONSORED OR CO-SPONSORED OVER 50 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE IN AND AROUND THE WORLD. THESE MEETINGS INCLUDED: - BEST OF ASCO CENTRAL - BEST OF ASCO EASTERN - BEST OF ASCO WESTERN - PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM -ASCO'S QUALITY CARE SYMPOSIUM - GI CANCERS SYMPOSIUM - GU CANCERS SYMPOSIUM - BREAST CANCER SYMPOSIUM - ASCO/AACR METHODS WORKSHOP INTERNATIONAL AFFAIRS MEETINGS AND COURSES: - BEST OF ASCO INTERNATIONAL (24) - JOINT SYMPOSIA (16) - ADVANCED CANCER COURSES (8) - MULTIDISCIPLINARY CANCER MANAGEMENT COURSES (4) ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR LIVE MEETINGS. THE DAILY NEWS PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AT THE LIVE EVENT AND ONLINE (THE ENTIRETY OF THE PRINT VERSIONS PLUS BONUS COVERAGE) TO ASCO MEMBERS AND TO THE GENERAL PUBLIC. THE DAILY NEWS PRODUCTS INCLUDE COVERAGE OF KEY EDUCATIONAL AND SCIENTIFIC SESSIONS, EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. 16471423 0 30934184 EDUCATIONAL PUBLICATIONS: ASCO PUBLISHES TWO EDUCATIONAL JOURNALS ADDRESSING CLINICAL ONCOLOGY THAT ARE AVAILABLE TO THE PUBLIC. JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS. THE JOURNALS INCLUDE ORIGINAL REPORTS, SELECTED EDITORIALS, COMMENTARIES, REVIEWS, AND OTHER WORK THAT RELATES TO THE CARE OF PATIENTS WITH CANCER. JCO IS TRANSLATED INTO A NUMBER OF LANGUAGES IN INTERNATIONAL EDITIONS, THERBY INCREASING ITS USE INTERNATIONALLY. 18524545 0 582313 QUALITY: THE ASCO QUALITY DEPARTMENT IS RESPONSIBLE FOR THE DEVELOPMENT OF EVIDENCE-BASED GUIDELINES, DEVELOPING AND VALIDATING QUALITY MEASURES IN ONCOLOGY, QUALITY IMPROVEMENT AND MEASUREMENT. PROGRAMS INCLUDE: - CANCERLINQ, AN INITIATIVE TO DEVELOP A RAPID LEARNING SYSTEM IN ONCOLOGY. THIS EFFORT IS INTENDED TO TRANSFORM THE WAY ONCOLOGISTS PRACTICE, LEARN, AND INTERACT WITH THEIR PATIENTS. CANCERLINQ IS A SYSTEM THAT TRACKS THE QUALITY OF CARE IN REAL TIME TO ENSURE PATIENTS GET ALL THE CARE THEY NEED AND NONE THEY DON'T, GAINS INSIGHTS FROM DEIDENTIFIED DATA ON THOUSANDS OF PATIENTS AND VISUALIZES PATIENTS' MEDICAL HISTORIES IN POWERFUL NEW WAYS. - QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. THE PROGRAM IS UNIQUE IN THE CANCER COMMUNITY AND HAS BEEN ACCEPTED BY THE AMERICAN BOARD OF INTERNAL MEDICINE AS A MECHANISM FOR SATISFYING PRACTICE EVALUATION AND IMPROVEMENT REQUIREMENTS FOR MAINTENANCE OF CERTIFICATION. ASCO SUPPORTS A NUMBER OF COLLABORATIVE GROUPS THAT USE QOPI WITHIN THEIR INITIATIVES TO DRIVE THEIR QUALITY IMPROVEMENT EFFORTS. OVER 700 PRACTICES NATIONWIDE, INCLUDING PRACTICES IN HAWAII, ALASKA, GUAM, AND PUERTO RICO, ARE ENROLLED IN THE PROGRAM. - QOPI CERTIFICATION PROGRAM. THE QOPI CERTIFICATION PROGRAM BUILDS UPON THE SUCCESS OF QOPI. QOPI CERTIFICATION DEMONSTRATES A COMMITMENT TO EXCELLENCE AND ONGOING QUALITY IMPROVEMENT IN THE HEMATOLOGY-ONCOLOGY OUTPATIENT PRACTICE. THE GOALS OF THE QOPI CERTIFICATION PROGRAM ARE TO: - PROMOTE HIGH QUALITY CANCER CARE AS DEFINED BY THE CLINICIAN EXPERTS. - PROVIDE A TRUSTED SOLUTION TO SATISFY EXTERNAL DEMAND FOR QUALITY ACTIVITIES. - REDUCE REDUNDANT PROGRAMS OR ADMINISTRATIVE BURDENS RELATED TO THE DEMONSTRATION OF QUALITY. THE QOPI CERTIFICATION PROGRAM IS CARRIED OUT BY A SPECIAL-PURPOSE LIMITED LIABILITY CORPORATION (LLC), ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM). THE SOLE MEMBER OF THIS LLC IS ASCO AND THE PRESIDENT IS ASCO'S CHIEF EXECUTIVE OFFICER. - NEW GUIDELINES AND ONGOING UPDATES. ASCO HAS PUBLISHED OVER 50 PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. 16715093 581108 139749 91000705 true true false true false false false false false false true true false false true true true false false true true true true false false false false true false true true false false false false false false false false false false false false false false true true true true false false true 411 0 true 479 true true true false false false false false false false false false X 18 18 false false false false true true true true true false false true true true true true true true true false CA NY VA X LINDA JENSEN CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 Julie M Vose MD MBA FASCO President 1.0 0.0 X X 0 0 0 Daniel F Hayes MD FASCO President-Elect 1.0 0.0 X X 0 0 0 Peter P Yu MD FASCO Immediate Past President 1.0 0.0 X X 500 0 0 Craig Nichols MD Treasurer 1.0 0.0 X X 0 0 0 Smita Bhatia MD MPH Board Member 1.0 0.0 X 0 0 0 Charles DBlankeMDFACPFASCO Board Member 1.0 0.0 X 500 0 0 Linda D Bosserman MD FACP Board Member 1.0 0.0 X 0 0 0 Walter J Curran JrMDFACR Board Member 1.0 0.0 X 0 0 0 Stephen B Edge MD FASCO Board Member 1.0 0.0 X 0 0 0 Paulo Hoff MD FACP Board Member 1.0 0.0 X 0 0 0 Hagop M Kantarjian MD Board Member 1.0 0.0 X 0 0 0 David Khayat MD PhD FASCO Board Member 1.0 0.0 X 0 0 0 Gary H Lyman MD FASCO Board Member 1.0 0.0 X 0 0 0 Neal J Meropol MD FASCO Board Member 1.0 0.0 X 0 0 0 Therese M Mulvey MD FASCO Board Member 1.0 0.0 X 0 0 0 J Chris Nunnink MD FASCO Board Member 1.0 0.0 X 0 0 0 Lillian L Siu MD FRCPC Board Member 1.0 0.0 X 0 0 0 Jedd Wolchok MD FASCO Board Member 1.0 0.0 X 0 0 0 W Charles Penley MD FASCO CCF Chair (non-voting) 1.0 1.0 X 0 0 0 Allen S Lichter MD FASCO CEO,Ex-officio Dir(non-voting) 30.0 7.5 X X 813542 0 21891 Paul Aines CPA CFO 30.0 7.5 X 168855 0 21543 Erin Hultman CPA Interim- CFO 30.0 7.5 X 231100 0 30235 Dina Michels Esq VP, General Counsel,Secretary 30.0 7.5 X 507500 0 38959 Richard Schilsky MD Chief Medical Officer 30.0 7.5 X 485000 0 31951 Nancy Daly MS MPH Executive Director, CCF 1.0 36.5 X 291000 0 34056 Kevin Fitzpatrick CEO CancerLinQ 37.5 0.0 X 165385 0 6272 Bernie Khoo Senior Dir Integrated Media 35.0 2.5 X 457500 0 38708 Rober Miller MD Senior Director Quality 37.5 0.0 X 328077 0 38963 Deborah Kamin RN PHD Senior Director Cancer Policy 37.5 0.0 X 266000 0 38213 Jean Colvard Senior Director Meeting Svcs 37.5 0.0 X 253000 0 25250 David Sampson Senior Director Journals 37.5 0.0 X 213500 0 30197 Krista Barnes Senior Director Member Svcs 37.5 0.0 X 186000 0 19860 Jamie Von Roenn MD Senior Director Education 37.5 0.0 X 336000 0 37182 Kristin Ludwig Senior Director Communications 37.5 0.0 X 256123 0 19576 Suzanne Brach Senior Director Marketing 37.5 0.0 X 231500 0 30759 Douglas Pyle Senior Director International 37.5 0.0 X 220000 0 34838 Kay Noll Senior Director Human Resource 37.5 0.0 X 222500 0 22747 Stephen Grubbs MD Senior Dir Clinical Affairs 37.5 0.0 X 172538 0 4980 5806120 0 526180 125 false true false THE CORKERY GROUP 260 Fifth Ave NEW YORK NY 10001 PUBLIC RELATIONS 827191 THRUUE INC 235 Main Street Suite 227 MADISON NJ 07940 STRATEGY CONSULTING 583491 ASTUTE TECHNOLOGY 11718 BOWMEN GREEN DR RESTON VA 20190 VIDEO RECORDING 572139 SAP AMERICA INC 3999 west chester pike NEWTON SQUARE PA 19073 TECHNOLOGY SERVICES 552421 POLSINELLI SHUGHART PC 1152 15th St NW WASHINGTON DC 20005 LEGAL 570768 17 13914277 46580 0 13960857 EDUCATION MEETINGS & PRODUCTS 900099 30708557 30708557 ADVERTISING 541800 16966383 16966383 PUBLICATIONS 511190 13967801 13967801 MEMBERSHIP 900099 13542455 13542455 EXHIBITS 900099 13051528 13051528 722062 139749 582313 88958786 3095028 3095028 0 2305014 2305014 1001902 1435930 -434028 0 -434028 -434028 78419484 79326661 -907177 -907177 -907177 0 0 0 MAILING LIST 511120 306781 306781 TENANT PARKING 900099 89100 89100 395881 107374361 71410090 17203768 4799646 3590038 3590038 0 581108 581108 0 6160643 4582343 1035180 543120 0 25467036 21461301 3310715 695020 2236149 1945450 290699 3704408 3222835 481573 2467269 2146524 320745 0 976757 505119 471638 87232 21808 65424 167802 167802 0 638394 638394 12726971 11217809 1484950 24212 496222 467281 28941 1724931 1574111 150820 8876784 7923853 900754 52177 0 3732150 3112613 503840 115697 4011275 3519602 481353 10320 0 10239848 9339981 819188 80679 0 0 2804644 2440041 280464 84139 470446 423401 47045 PRINTING & PRODUCTION 6564346 6518867 9600 35879 DEVELOPMENT FEE TO CCF 2200000 2200000 POSTAGE & SHIPPING 1648953 1605288 29015 14650 UBI TAX 2326667 2326667 2851114 2306863 544251 106751187 91000705 11894589 3855893 300 300 5962166 8897670 0 0 5894637 7098511 0 0 0 0 0 0 0 0 3076387 4306960 68916703 18003850 51844763 50912853 119914888 113410480 21933705 23365980 0 0 0 0 8912434 1320090 217539280 209312844 5304131 6260807 0 0 21067057 25274886 38400000 38400000 0 0 0 0 0 0 0 0 48038446 40261929 112809634 110197622 X 104729646 99115222 0 0 0 0 104729646 99115222 217539280 209312844 X 623174 -6621590 383992 X X false true X true false X 7731584 9951001 8477875 9775055 13960857 49896372 72435660 73138765 76312383 83008682 88958786 393854276 0 0 0 80167244 83089766 84790258 92783737 102919643 443750648 10563934 13094217 11456835 12876427 13914277 61905690 0 10563934 13094217 11456835 12876427 13914277 61905690 381844958 2794882 4333604 5333603 5821197 6401944 24685230 0 2794882 4333604 5333603 5821197 6401944 24685230 2108381 3049601 3403799 3584676 3133751 15280208 306781 306781 85070507 90472971 93527660 102189610 112762119 484022867 0.78890 0.79266 0.05100 0.04243 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8424 203960 212384 97685735 97898119 1000000 250000 1000000 1000000 1000000 1000000 4000000 6000000 170099 170479 171707 212384 724669 250000 250000 250000 250000 1000000 1500000 1320 12065 10098 8424 31907 7342644 7342677 46874634 9005375 37869259 11034519 6995041 4039478 3664873 2003434 1661439 50912853 ALPHAKEYS DOUBLE BLACK DIAMOND 10439492 F UBS MILLENNIUM FUND (OFFSHORE) 12926488 F 23365980 0 LIABILITY UNDER INTEREST RATE 15811117 TAXABLE BOND PAYABLE 22231178 DUE TO AFFILIATE 2219634 40261929 X 101934299 -6621590 383992 -6237598 108171897 638394 -1435930 -797536 107374361 107548723 1435930 1435930 106112793 638394 638394 106751187 PART X, LINE 2 UNDER ASC TOPIC 740-10, ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, THE ORGANIZATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED AN EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE DECEMBER 31, 2012. PART XI, LINE 2D AND 4B - OTHER ADJUSTMENTS LINE 2D GAIN ON INTEREST RATE SWAP 383,992 LINE 4B RENTAL EXPENSES -1,435,930 PART XII, LINE 2D - OTHER ADJUSTMENTS RENTAL EXPENSE 1,435,930 true East Asia and the Pacific 0 0 Program Services OUTREACH & EDUCATIONAL 87414 Europe (Including Iceland and Greenland) 0 0 Program Services OUTREACH & EDUCATIONAL 97795 Middle East and North Africa 0 0 Program Services OUTREACH & EDUCATIONAL 105801 North America 0 3 Program Services OUTREACH & EDUCATIONAL 23078 South America 0 0 Program Services OUTREACH & EDUCATIONAL 75148 South Asia 0 0 Program Services OUTREACH & EDUCATIONAL 92785 Sub-Saharan Africa 0 0 Program Services OUTREACH & EDUCATIONAL 72239 Central America and the Caribbean 0 0 Program Services OUTREACH & EDUCATIONAL 26848 Central America and the Caribbean 0 0 Investments OUTREACH & EDUCATIONAL 10411975 0 3 0 3 10993083 10993083 Europe (Including Iceland and Greenland) Support of 10 UICC ICRETT fellows 45800 CHECK Europe (Including Iceland and Greenland) Support for 3 Flims Workshop 10500 CHECK 2 IDEA award East Asia and the Pacific 3 3620 CASH/CHECK 13747 TRAVEL BOOK IDEA award Europe (Including Iceland and Greenland) 2 2200 CASH/CHECK 6044 TRAVEL BOOK IDEA award Middle East and North Africa 4 4720 CASH/CHECK 16300 TRAVEL BOOK IDEA award North America 1 1100 CASH/CHECK 3485 TRAVEL BOOK IDEA award South America 3 3460 CASH/CHECK 11470 TRAVEL BOOK IDEA award South Asia 3 3620 CASH/CHECK 14814 TRAVEL BOOK IDEA award Sub-Saharan Africa 3 3460 CASH/CHECK 10892 TRAVEL BOOK IDEA award Central America and the Caribbean 1 1100 CASH/CHECK 4234 TRAVEL BOOK true false false false false false SCHEDULE F, PART I, LINE 1 INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS PROVIDE SUPPORT FOR EARLY-CAREER ONCOLOGISTS IN DEVELOPING COUNTRIES TO LEARN ABOUT ONCOLOGY CARE AND RESEARCH BY ESTABLISHING STRONG RELATIONSHIPS WITH LEADING ASCO ONCOLOGISTS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. RECIPIENTS LEARN ABOUT QUALITY CANCER CARE AND RESEARCH BY ATTENDING THE ASCO ANNUAL MEETING AND VISITING THEIR MENTOR'S CANCER CENTER IN THE UNITED STATES AND CANADA. RECIPIENTS ARE EXPECTED TO SHARE THE KNOWLEDGE AND TRAINING THEY RECEIVE THROUGH THE PROGRAM WITH COLLEAGUES IN THEIR HOME COUNTRIES ONCE THEY RETURN. IDEAS ARE PROVIDED TO RECIPIENTS BASED ON MERIT THROUGH A PEER REVIEW PROCESS USING ESTABLISHED ELIGIBILITY CRITERIA. IDEA RECIPIENTS ARE REQUIRED TO AGREE TO TERMS AND CONDITIONS APPLICABLE TO THE IDEA, ARE REQUIRED TO COMMUNICATE WITH THEIR MENTORS, TO ATTEND ALL IDEA-RELATED EVENTS, TO SUBMIT EVALUATIONS AFTER THE ANNUAL MEETING AND MENTOR SITE VISIT, AND TO SUBMIT ONE-YEAR REPORTS. true Conquer Cancer Foundation 2318 Mill Rd Ste 800 Alexandria VA 22314 131825919 501 (c) (3) 3058000 Contribution CONTROL ICRETT FELLOWS University of Nebraska Medical Center 985520 Nebraska Med CTR Omaha NE 68198 751835298 501 (c) (3) 157092 Contribution ORGANIZATION) Palo Alto Medical Foundation 795 El Camino Rd Palo Alto CA 94301 521983273 501 (c) (3) 99709 Contribution National Academy of Sciences 2101 Const Ave NW Washington DC 20418 850357897 501 (c) (3) 53000 Contribution Regents of the University of Michigan 300 N Ingalls St Ann Arbor MI 48109 362192800 501 (c) (3) 49897 Contribution Testicular Cancer Commons 222 SW Harrison 10B Portland OR 97201 530196932 501 (c) (3) 30706 Contribution Komen National Race for the Cure 1911 N Ft Myer Dr 112 Arlington VA 22209 530196577 501 (c) (3) 25000 Contribution Duke University Medical Center 2424 Erwin Rd Suite 601 Durham NC 27705 311667995 501 (c) (3) 25000 Contribution University of Chicago 1427 E 60th St Suite 120 Chicago IL 60637 236251648 501 (c) (3) 21089 Contribution Washington Hospital Center Foundation 110 Irving St NW Washington DC 20010 560532129 501 (c) (3) 20000 Contribution Friends of Cancer Research 3299 K Street NW Washington DC 20007 362177139 501 (c) (3) 15000 Contribution Memorial Sloan Ketting Institute PO Box 026338 New York NY 10087 941156581 501 (c) (3) 10545 Contribution National Coalition for Cancer Survivorship 1010 Wayne Avenue 770 Silver Spring MD 20910 131924236 501 (c) (3) 10000 Contribution Health Volunteers Overseas 1900 L St NW 310 Washington DC 20036 521272129 501 (c) (3) 10000 Contribution 14 SCHEDULE I, PART I, LINE 1 ASCO provides assistance to 501c3 organizations that serve the cancer community. X true true X X X X X X false false false true true false false true true true Allen S Lichter MD FASCO CEO,Ex-officio Dir(non-voting) 655542 0 98000 0 60000 0 19875 0 2016 0 835433 0 0 Richard Schilsky MD Chief Medical Officer 479000 0 6000 0 0 0 19875 0 12076 0 516951 0 0 Paul Aines CPA CFO 164855 0 4000 0 0 0 11877 0 9666 0 190398 0 0 Erin Hultman CPA Interim- CFO 181600 0 49500 0 0 0 13620 0 16615 0 261335 0 0 Dina Michels Esq VP, General Counsel,Secretary 507500 0 0 0 0 0 19875 0 19084 0 546459 0 0 Nancy Daly MS MPH Executive Director, CCF 285000 0 6000 0 0 0 19875 0 14181 0 325056 0 0 Kevin Fitzpatrick CEO CancerLinQ 140385 0 25000 0 0 0 0 0 6272 0 171657 0 0 Bernie Khoo Senior Dir Integrated Media 376500 0 81000 0 0 0 19875 0 18833 0 496208 0 0 Rober Miller MD Senior Director Quality 298077 0 30000 0 0 0 19875 0 19088 0 367040 0 0 Deborah Kamin RN PHD Senior Director Cancer Policy 255000 0 11000 0 0 0 19125 0 19088 0 304213 0 0 Jean Colvard Senior Director Meeting Svcs 241000 0 12000 0 0 0 18075 0 7175 0 278250 0 0 Kristin Ludwig Senior Director Communications 242000 0 14123 0 0 0 18112 0 1464 0 275699 0 0 Suzanne Brach Senior Director Marketing 221000 0 10500 0 0 0 16575 0 14184 0 262259 0 0 Douglas Pyle Senior Director International 210000 0 10000 0 0 0 15750 0 19088 0 254838 0 0 Kay Noll Senior Director Human Resource 210500 0 12000 0 0 0 15788 0 6959 0 245247 0 0 David Sampson Senior Director Journals 203500 0 10000 0 0 0 15262 0 14935 0 243697 0 0 Krista Barnes Senior Director Member Svcs 180000 0 6000 0 0 0 13500 0 6360 0 205860 0 0 Jamie Von Roenn MD Senior Director Education 330000 0 6000 0 0 0 19875 0 17307 0 373182 0 0 Stephen Grubbs MD Senior Dir Clinical Affairs 142538 0 30000 0 0 0 0 0 4980 0 177518 0 0 PART I, LINE 1A A housing allowance is provided to the CEO, which is considered part of the CEO's compensation and addressed in the CEO's written employment contract. The allowance is treated as taxable compensation. PART I, LINE 5A & 5B PERFORMANCE-BASED BONUS PAYMENTS CAN BE MADE TO SOME EMPLOYEES LISTED ON SCHEDULE J AND INCLUDED AS PART OF THE TOTAL COMPENSATION. THE BONUS PAYMENTS ARE NOT ON A FIXED BASIS BUT RATHER ARE BASED ON PERFORMANCE AND DETERMINED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. PART I, LINE 8 Certain amounts paid or accrued to the CEO and the VP/GC were pursuant to contracts that were subject to the initial contract exception described in Treasury Regulation Section 53 4958-4(A)(3). A INDUSTRIAL DEVELOPMENT AUTHORITYCITY OF ALEXANDRI 521381432 01530lad2 2012-08-01 38400000 Buy/Buildout 5 floors HQ building false false false A 0 0 38400000 0 0 0 0 0 0 38400000 0 0 2008 false false true true A false false true true false 0.00000 0.00500 0.00500 false false false true A false false false false true true fms wentworth 30. false false false 0 false true A true PART IV, QUESTION 3 ASCO has an interest rate swap agreement with FMS Wentworth Bank through 2038. ASCO makes fixed interest payments at a 3.587% rate. Variable swap payments, based on one-month LIBOR, received from the swap counterparty are used to make the variable interest payments as they come due. These interest rate swap agreements qualify as a derivative instrument and are used to mitigate the effect of interest rate fluctuations. FORM 990, PART III, LINE 4D CANCER POLICY AND CLINICAL AFFAIRS: ASCO'S CANCER POLICY AND CLINICAL AFFAIRS DEPARTMENT ADDRESSES POLICY ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, CANCER RESEARCH, CARE AND PREVENTION. THE DEPARTMENT WORKS WITH VOLUNTEER COMMITTEES AND ASCO LEADERS TO SHAPE POLICY, LAW AND REGULATION ON ISSUES OF IMPORTANCE IN ONCOLOGY. THE DEPARTMENT'S PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING PATIENT-ORIENTED RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ACTIVITIES INCLUDE HOTLINES, TOOLS, EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. CANCER POLICY AND CLINICAL AFFAIRS STAFF INTERACT AND COLLABORATE ON A REGULAR BASIS WITH ASCO STATE AND REGIONAL AFFILIATES, OTHER MEDICAL SPECIALTY AND PROFESSIONAL SOCIETIES, CONGRESS, THE ADMINISTRATION, AND PATIENT ADVOCATE ORGANIZATIONS TO ADVANCE COMMON GOALS RELATED TO CANCER RESEARCH AND QUALITY CARE. ASCO'S COST OF CARE TASK FORCE COLLABORATES WITH QUALITY AND EDUCATION TEAMS TO DISSEMINATE RECOMMENDATIONS TO ONCOLOGISTS. ASCO CONTINUES ITS POLICY WORK THIS YEAR TO ADDRESS CANCER CARE AND RESEARCH ISSUES IN THE AREAS OF SURVIVORSHIP, TOBACCO USE, HEREDITARY CANCER RISK, AND CARE FOR PATIENTS WITH ADVANCED CANCER. ALSO, AS PART OF A COMPREHENSIVE EFFORT TO DETERMINE WORKFORCE CAPACITY TO MEET PROJECTED INCREASES IN CANCER INCIDENCE AND TO IDENTIFY INNOVATIVE CARE MODELS, ASCO LAUNCHED A MULTI-PRONGED RESEARCH EFFORT TO ESTABLISH AN ONCOLOGY CENSUS, IDENTIFY TRENDS IN PRACTICE ECONOMICS, AND DOCUMENT CARE PATTERNS. ASCO WORKED WITH OTHER ADVOCACY GROUPS TO ADVOCATE WITH TO THE DEPARTMENTS OF HEALTH AND HUMAN SERVICES, TREASURY, AND LABOR TO ENCOURAGE COMPREHENSIVE IMPLEMENTATION OF THE CLINICAL TRIALS COVERAGE PROVISION OF THE AFFORDABLE CARE ACT. FINALY, THE SOCIETY WORKED IN COLLABORATION WITH FDA AND OTHER ONCOLOGY STAKEHOLDERS TO REFINE CLINICAL ENDPOINTS USED IN CANCER CLINICAL TRIALS, OPTIMIZE DATA COLLECTION FOR SUPPLEMENTAL DRUG APPLICATIONS, AND TO ADDRESS THE ONGOING CHALLENGES PRESENTED BY PERSISTENT SHORTAGES OF CRITICAL CHEMOTHERAPY DRUGS. THE STATE/REGIONAL AFFILIATE PROGRAM: THE AFFILIATE PROGRAM WAS CREATED IN 1993 TO BETTER ADDRESS ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, AND TO FACILITATE ASCO'S OWN ADVOCACY PROGRAMS. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. THE STATE/REGIONAL AFFILIATE PROGRAM IS NOT A LEGAL AFFILIATION WITH ASCO AND THERE IS NO FINANCIAL RESPONSIBILITY TO THE STATE AFILIATES. FEDERAL POLICIES IMPACTING CANCER CARE AND RESEARCH: ASCO REVIEWS AND FREQUENTLY COMMENTS ON POLICIES ISSUED BY FEDERAL AGENCIES, INCLUDING THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS), FOOD AND DRUG ADMINISTRATION (FDA), AND NATIONAL INSTITUTES OF HEALTH (NIH). STAFF AND VOLUNTEERS ALSO ACTIVELY PARTICIPATE IN AMERICAN MEDICAL ASSOCIATION (AMA) PROCESSES FOR DEVELOPMENT OF NEW CPT CODES AND VALUATION OF CODES THROUGH THE AMA/SPECIALTY SOCIETY RELATIVE VALUE SCALE UPDATE COMMITTEE (RUC). MEMBER RELATIONS AND INFORMATION ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 40,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS. ASCO CONNECTION IS THE OFFICIAL BIMONTHLY MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO. IT IS THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CUTTING EDGE RESEARCH, BEST PRACTICES STANDARDS, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE, AND OPPORTUNITIES TO CREATE GROUPS. EXPENSES $1,946,520. INCLUDING GRANTS OF $581,108. REVENUE $75,640. COMMUNICATIONS AND PATIENT INFORMATION ASCO PROVIDES THE PUBLIC, INCLUDING PATIENTS, THE MEDIA, LEGISLATORS, PHYSICIANS AND OTHER HEALTH CARE PROFESSIONALS, WITH ACCURATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. ASCO HAS A FREE PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), AVAILABLE TO THE PUBLIC, INCLUDING PATIENTS, THEIR CAREGIVERS, FAMILY MEMBERS AND FRIENDS, THE MEDIA AND HEALTH CARE PROFESSIONALS, THAT PROVIDES UP-TO-DATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. THE SITE OFFERS MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER. IN ADDITION TO ITS WEBSITE CONTENT, ASCO OFFERS PRINTED MATERIALS FOR PATIENTS, SUCH AS: CANCER.NET'S GUIDES TO CANCER (DETAILED GUIDES COVERING SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT,CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR), ASCO ANSWERS FACT SHEETS (A SERIES OF FACT SHEETS THAT PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, QUESTIONS TO ASK THE DOCTOR), BOOKLETS ON TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. ADDITIONAL RESOURCES AVAILABLE ON CANCER.NET. ASCO ALSO PROVIDES THE FOLLOWING INFORMATIONAL SERVICES TO THE PUBLIC: FIND AN ONCOLOGIST DATABASE: A FREE SEARCHABLE DATABASE OF ASCO MEMBERS BY SPECIALTY OR LOCATION FOR THOSE IN NEED OF A SPECIALIST. CANCER ADVANCES: SUMMARIES OF RESEARCH ADVANCES IN CLINICAL ONCOLOGY FROM THE JOURNAL OF CLINICAL ONCOLOGY, ASCO'S ANNUAL MEETINGS, AND ASCO SYMPOSIA. WHAT TO KNOW: ASCO'S GUIDELINES: PATIENT-FRIENDLY GUIDES BASED ON ASCO'S CLINICAL PRACTICE GUIDELINES FOR PHYSICIANS. RESEARCH AND MEETINGS: INFORMATION ON ASCO'S ANNUAL MEETINGS AND SYMPOSIA, VIRTUAL LECTURES, AND ASCO'S EXPERT PERSPECTIVE ON CANCER NEWS. MULTIMEDIA: MEDICAL ILLUSTRATIONS, MOBILE APP, VIDEOS, AND PODCASTS ON TOPICS SUCH AS: CANCER RESEARCH, TREATMENT, AND COPING. EXPERT INFORMATION FROM ASCO: ASCO EXPERTS ANSWER QUESTIONS ABOUT CURRENT TOPICS IN CANCER CARE, TREATMENT, AND RESEARCH. CANCER.NET FEATURE ARTICLES: WEEKLY ARTICLES DESIGNED TO PROVIDE IN-DEPTH INFORMATION ON TOPICS OF INTEREST, AS WELL AS PRACTICAL INFORMATION ON CANCER CARE AND TREATMENT. ASCO CANCER TREATMENT SUMMARY FORMS: PRINTABLE FORMS PATIENTS AND THEIR DOCTORS CAN COMPLETE TO HELP KEEP TRACK OF TREATMENT PLANS AND FOLLOW-UP CARE PLANS. CANCER.NET EN ESPANOL: TRANSLATED CONTENT ON THE TREATMENT OF COMMON CANCER TYPES, MANAGING SIDE EFFECTS, AN INTRODUCTION TO CLINICAL TRIALS, SURVIVORSHIP, AND ASCO'S GUIDELINES. SEVERAL PRINTED PIECES ARE ALSO AVAILABLE IN SPANISH. EXPENSES $6,852,442. INCLUDING GRANTS OF $0. REVENUE $16,299. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2015, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. NO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCOS PROFITS OR EXCESS DUES OR A SHARE OF ASCOS NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP WITH VOTING RIGHTS AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. 2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 70, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. 2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 3. HONORARY MEMBERS. 3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. 3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION A, LINE 7B ASCOS CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE VICE PRESIDENT AND GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF); THE PRESIDENT OF ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM AND D/B/A CANCERLINQ); THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF DIRECTORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2015. VICE PRESIDENT/GENERAL COUNSEL: THE COMPENSATION OF THE VICE PRESIDENT/GENERAL COUNSEL (VP/GC) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE VP/GC WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE VP/GC AND ASCO ADDRESSES COMPENSATION OF THE VP/GC. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP/GC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2015. CHIEF FINANCIAL OFFICER (CFO). THE COMPENSATION OF THE CHIEF FINANCIAL OFFICER (CFO) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE CFO WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2015. EXECUTIVE DIRECTOR OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF): THE EXECUTIVE DIRECTOR OF CCF IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED AND APPROVED THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2015. SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY: THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2015. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE, AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART XI, LINE 9 GAIN ON INTEREST RATE SWAP 383,992 FORM 990 PART IX LINE 11G DESCRIPTION:COMMISSIONS TOTAL FEES:3430566 FORM 990 PART IX LINE 11G DESCRIPTION:PUBLIC RELATIONS COORDINATION TOTAL FEES:1474139 FORM 990 PART IX LINE 11G DESCRIPTION:OTHER PROFESSIONAL SERVICES TOTAL FEES:7822266 ASCO INSTITUTE FOR QUALITY LLC 2318 MILL ROAD ALEXANDRIA VA 22314 271629211 QOPI CERT PRO VA 591229 1470346 ASCO ASCO LEASING LLC 2318 MILL ROAD ALEXANDRIA VA 22314 273378225 RENTAL VA 1023426 148810 ASCO CANCERLINQ LLC 2318 MILL ROAD ALEXANDRIA VA 22314 472315885 QUALITY IMPRO VA 7530656 2904754 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL ROAD ALEXANDRIA VA 22314 311667995 Grants VA 501C3 509(A)(1) true true true true false true false false false true false false true true true true true false false